Abstract The controlled substance “ibogaine” is reported to have unique addiction-interrupting properties. Due to its illegal status, the drug's application for treating substance dependency has been explored by a network of addicts and harm reduction activists in underground and off-shore clinics. The article investigates the strategies that practitioners have adopted to mitigate harm from...
Ibogaine, derived from the Iboga (Tabernanthe iboga), a shrub of central Africa, has a history of medical and entheogenic ritual use. Its modern use followed the serendipitous discovery, among heroin users in 1962, that it interrupted heroin addiction. Efforts to engage the scientific community in the clinical science of ibogaine had limited success but led to an underground treatment movement...
This chapter details the therapy protocols involving ibogaine utilized at The Mission Within (https://missionwithin.org) in Baja California, Mexico, as described by its founder and research director, Dr. Martin Polanco, along with psychedelic preparation/integration counselor and therapeutic facilitator, Dr. Mia Black. The chapter describes: Their personal development as ibogaine therapists and...
Introduction: Currently, 5% of the global adult population is affected by Alcohol Use Disorder (AUD), and alcohol consumption is linked to 3% of all deaths worldwide, being one of the main contributors to various diseases and mortality.Although the medications currently available demonstrate some efficacy, their adverse effects and the relatively long duration of treatment can hinder...
Ibogaine, a non-classical psychedelic, has gained increasing attention as a potential treatment for substance use disorders (SUD); however, a lack of commercial interest and safety-related concerns limit its clinical development. This cross-sectional study investigates the current landscape of clinical trials involving ibogaine, a non-classical psychedelic, focusing on its safety and efficacy....
Clinical ToxicologyMarch 1, 2025Ella P Edwards, Laurence A Gray, Muhammad E M O Elamin et al.2 citations
Ibogaine is a psychoactive alkaloid derived from the root bark of the West African shrub Tabernanthe iboga. It is not licensed in the United Kingdom but is used by individuals to alleviate drug or alcohol use. A retrospective analysis of telephone enquiries involving ibogaine between 1 January 2012 and 31 December 2022 to the United Kingdom National Poisons Information Service was performed....
Anecdotal reports and preliminary clinical trials suggest that the psychoactive alkaloid ibogaine and its active metabolite noribogaine have powerful anti-addictive properties, producing long-lasting therapeutic effects across a range of substance use disorders and co-occurring neuropsychiatric diseases such as depression and post-traumatic stress disorder. Here we report a gram-scale,...
Psychedelics show promise in treating psychiatric disorders. Therapeutic effects appear to involve activation of the 5-Hydroxytryptamine 2A receptor (5-HT2AR), a G protein-coupled receptor (GPCR). Several SNPs of the 5-HT2AR naturally occur, which are associated with differences in receptor function and altered responsiveness to treatments. New compounds suspected to act at the 5-HT2AR are...
The 2024 North American Conference of Clinical Toxicology and the annual American College of Emergency Physicians Scientific Assembly yielded several thought-provoking ideas for emergency physicians, some that you should be employing and another, like this first one, that is not ready for the big time in the ED.